Androgen Antagonists
Edetic Acid
/ analogs & derivatives
Gallium Isotopes
Gallium Radioisotopes
Hormones
Humans
Male
Neoplasm Recurrence, Local
/ diagnostic imaging
Oligopeptides
Positron Emission Tomography Computed Tomography
Prospective Studies
Prostate-Specific Antigen
Prostatic Neoplasms
/ diagnostic imaging
Salvage Therapy
Biochemical persistence
Biochemical recurrence
PSMA
PSMA PET
Prostate cancer
Prostate cancer change of management
Salvage radiotherapy
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
17
11
2019
accepted:
02
04
2020
pubmed:
22
4
2020
medline:
15
5
2021
entrez:
22
4
2020
Statut:
ppublish
Résumé
The primary objective is to assess the efficacy of Inclusion criteria include (1) histologically diagnosed PCa; (2) previous radical therapy; (3) proven biochemical recurrence (BCR) or biochemical persistence (BCP); (4) hormone-sensitive PCa (HSPC); (5) androgen deprivation therapy (ADT)-free for at least 6 months; (6) PSA < 1.5 ng/mL or any PSA in case of negative choline-PET/CT (n = 38). Changes in clinical management were defined by multidisciplinary tumour-board. Clinical settings were BCP (group-1, n = 25); first-time BCR (group-2, n = 121); BCR after salvage therapy (group-3, n = 77). Two hundred twenty-three (223) consecutive patients were enrolled: median PSA = 0.65 ng/mL (0.2-8.9) and median PSAdt = 9.3 months (0.4-144.6). 96.9% received RP as primary therapy. This study attested the overall good performance of
Identifiants
pubmed: 32314028
doi: 10.1007/s00259-020-04809-8
pii: 10.1007/s00259-020-04809-8
doi:
Substances chimiques
Androgen Antagonists
0
Gallium Isotopes
0
Gallium Radioisotopes
0
Hormones
0
Oligopeptides
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2804-2815Références
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.
doi: 10.1016/j.eururo.2016.08.002
Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852–63.
doi: 10.1016/j.eururo.2014.09.004
Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035–41.
doi: 10.1200/JCO.2006.08.9607
Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, et al. Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur Urol. 2017. https://doi.org/10.1016/j.eururo.2017.07.026 .
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53.
doi: 10.1200/JCO.2017.75.4853
Ploussard G, Gandaglia G, Borgmann H, de Visschere P, Heidegger I, Kretschmer A, et al. EAU-YAU Prostate Cancer Working Group. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.10.041 .
Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, et al. (68)Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging. 2019;46(1):11–9.
doi: 10.1007/s00259-018-4066-4
Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. (68)Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59(2):230–7.
doi: 10.2967/jnumed.117.201749
Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients [published correction appears in Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1781]. Eur J Nucl Med Mol Imaging. 2017;44(8):1258–68.
doi: 10.1007/s00259-017-3711-7
Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Comparison of (68)Ga-PSMA-11 and (18)F-fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J Nucl Med. 2018;59(5):789–94.
doi: 10.2967/jnumed.117.203257
Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019. https://doi.org/10.1016/S1470-2045(19)30415-2 .
Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020; 77(4):403–17.
Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, et al. (68)Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2019;46(1):31–9.
doi: 10.1007/s00259-018-4189-7
Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, Briganti A, et al. Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04505-2 .
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59(3):469–78.
doi: 10.2967/jnumed.117.198119
Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274–8.
doi: 10.1097/01.ju.0000097124.21878.6b
Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate Cancer. Pharmaceuticals (Basel). 2014;7(7):779–96.
doi: 10.3390/ph7070779
Fendler WP, Eiber M, Beheshti M, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.
doi: 10.1007/s00259-017-3670-z
Fanti S, Minozzi S, Morigi JJ, et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. 2017;44(10):1622–35.
doi: 10.1007/s00259-017-3725-1
Caroli P, Sandler I, Matteucci F, et al. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. 2018;45(12):2035–44.
doi: 10.1007/s00259-018-4067-3
Rauscher I, Duwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, et al. Efficacy, predictive factors, and prediction nomograms for (68)Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol. 2018;73(5):656–61.
doi: 10.1016/j.eururo.2018.01.006
Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, et al. The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients. Eur Urol. 2016;69(6):1142–8.
doi: 10.1016/j.eururo.2015.12.010
Ceci F, Herrmann K, Hadaschik B, Castellucci P, Fanti S. Therapy assessment in prostate cancer using choline and PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):78–83.
doi: 10.1007/s00259-017-3723-3
Bianchi L, Borghesi M, Schiavina R, et al. Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database [published online ahead of print, 2020 Jan 31]. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04696-z .
Pereira Mestre R, Treglia G, Ferrari M, Pascale M, Mazzara C, et al. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: a meta-analysis. Eur J Clin Investig. 2019 Mar;49(3):e13063.
doi: 10.1111/eci.13063
Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, et al. Impact of (68)Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med. 2018;59(3):434–41.
doi: 10.2967/jnumed.117.202945
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63.
Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, et al. (68)Ga-PSMA-11 PET detects residual prostate cancer after prostatectomy in a multicenter retrospective study. J Urol. 2019:101097JU0000000000000417. https://doi.org/10.1097/JU.0000000000000417 .
Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clin Nucl Med. 2016 Jul;41(7):515–21.
doi: 10.1097/RLU.0000000000001197
Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.
doi: 10.1007/s00259-013-2525-5
Schwenck J, Rempp H, Reischl G, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44(1):92–101.
doi: 10.1007/s00259-016-3490-6
Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019;19(1):18.
doi: 10.1186/s12885-018-5200-1